Evaluation of the Efficacy of Pharmacotherapy for Decompensated Intestinal Dysbacteriosis in Cats

The treatment of intestinal dysbiosis in animals remains one of the most complex and urgent problems in veterinary medicine to this day. Recently, a steady increase in pathologies has been recorded, accompanied by the development of disorders of the gastrointestinal tract of various etiologies in animals. Despite the constant improvement of methods for correcting the intestinal microbiota, the occurrence of dysbacteriosis in various pathological processes not only does not decrease, but, on the contrary, increases. Therefore, the choice of the optimal therapeutic regimen for the correction of the most severe decompensated degree of intestinal dysbacteriosis in cats is an important area of scientific research. The article shows that in case of decompensated intestinal dysbacteriosis in cats, the administration of the probiotic “Lactobifadol” in combination with the prebiotic “Vetelact” and the immunomodulator “Azoksivet” against the background of infusion therapy is the most effective, as evidenced by the registration of an overall clinical improvement of 1.28 times (p < 0.001) faster, when compared with animals of the group C1. At the same time, normalization of appetite, unpleasant odor from the oral cavity and the nature of fecal matter occurs in cats of group C3 1.40 days (p < 0.05), 1.60 days (p < 0.01) and 1.80 days (p < 0.01) earlier, according to compared with animals that were corrected according to scheme C1.